Project Grant R44CA297994
Award Date
1/13/25
Completion Date
12/31/26
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $665,000 to support the development and clinical testing of MT-601, a novel multi-tumor associated antigen (MTAA)-specific T-cell therapy for the treatment of non-Hodgkin lymphoma (NHL). The key objectives of this project are to manufacture the MT-601 product and conduct a Phase 1 clinical trial evaluating its safety and efficacy in NHL patients who have relapsed after prior CD19...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Transcode Therapeutics, Inc. will support the Phase I clinical testing of a novel therapeutic agent, MN-anti-miR10b, for the treatment of metastatic cancer. The $1,011,207 award, granted on Sep 4, 2024, will enable the completion of IND-enabling studies and initiation of a Phase Ia dose-escalation trial in patients with advanced solid cancers. This first-in-class therapy leverages the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will support research to investigate the role of natural killer (NK) cells in melanoma tumor invasion and immune evasion. The $217,863 award to the University of Colorado-Denver will use advanced techniques such as multiplexed immunohistochemistry, single-cell spatial transcriptomics, and patient-derived organoid models to evaluate how the KIR/HLA axis impacts the function of decidual-like NK...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded The Johns Hopkins University a $630,781 Project Grant (R01CA293906) on April 25, 2025 to develop engineered lipid nanoparticle (LNP) and microgel matrix formulations to program Th1/Th2 immune responses for cancer immunotherapy. The key objectives are to: 1) develop mRNA LNP formulations capable of eliciting dual or biased Th1/Th2 immune responses using machine learning; 2) engineer mRNA LNP-loaded microgels as an...
The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
The National Cancer Institute (NCI) awarded a $657,121 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, awarded on December 12, 2024, will fund research to develop an effective dendritic cell therapy to treat leptomeningeal disease (LMD), which occurs in 5% of advanced stage breast cancer patients and has a very poor prognosis. The key products and services to be delivered include:...